Defeating SARS-Cov-2 with Caflanone

A superior therapeutic and preventative prophylactic

Vilotos Shield Icon

Vilotos Pharmaceuticals is a drug development and research company focused on virology. 

The company has a collaboration with Flavocure Biotech, Inc., for the identification and development of certain natural molecules. The company is actively pursuing some of the most virulent diseases, with a focus on SARS-Cov-2 (COVID-19).

In light of compelling scientific data, a panel of researchers have concluded that the drug Caflanone should be considered for clinical trials.  This effort has been named ENDEAVOR-1 – Beating COVID-19.

Vilotos Pharmaceuticals is a Maryland based pharmaceutical company specialized in developing novel drugs for the prevention and treatment of endemic and emerging viruses.

Vilotos has collaborated with Harvard Medical School and Flavocure Biotech, Inc. on development of the molecules targeting SARS-Cov-2 (Covid 19).

Caflanone is a small molecule belonging to the flavonoid class of polyphenols. In preclinical studies, Caflanone inhibited the hCov-OC43 human Coronavirus with an EC50 of 0.42 µM.

Our Mission

The growing novel coronavirus, SARS-CoV-2, pandemic has resulted in over 4.6 million infections and 300,000 deaths as of May 20, 2020 according to statistics from the World Health Organization . Identification of effective antiviral agents to combat the SARS-CoV-2 is urgently needed.